Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
It is intended for contrast enhancement in MRI scans
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Dilip Shanghvi to continue as the Executive Chairman of the Board
Globally, BRUKINSA is approved in more than 70 countries
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
